Wen-Chun Liu to Humans
This is a "connection" page, showing publications Wen-Chun Liu has written about Humans.
Connection Strength
0.061
-
Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Front Immunol. 2019; 10:756.
Score: 0.007
-
Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus. J Pathol. 2017 10; 243(2):176-192.
Score: 0.006
-
Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. PLoS Pathog. 2021 08; 17(8):e1009758.
Score: 0.002
-
Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. Cell Rep Med. 2021 08 17; 2(8):100369.
Score: 0.002
-
Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. Hum Pathol. 2021 08; 114:110-119.
Score: 0.002
-
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat Biomed Eng. 2021 08; 5(8):815-829.
Score: 0.002
-
Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021 08; 34(8):1456-1467.
Score: 0.002
-
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell. 2021 05 13; 184(10):2618-2632.e17.
Score: 0.002
-
Animal models for COVID-19. Nature. 2020 10; 586(7830):509-515.
Score: 0.002
-
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020 09; 58(1):e108.
Score: 0.002
-
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 10; 586(7827):113-119.
Score: 0.002
-
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020 05 28; 181(5):1036-1045.e9.
Score: 0.002
-
Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based combination antiretroviral therapy. Medicine (Baltimore). 2019 Jun; 98(26):e16235.
Score: 0.002
-
Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Int J Antimicrob Agents. 2019 Jul; 54(1):35-42.
Score: 0.002
-
Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J Clin Invest. 2018 11 01; 128(11):4992-4996.
Score: 0.002
-
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep. 2018 09 12; 8(1):13699.
Score: 0.002
-
Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations. J Biomed Sci. 2018 Jun 02; 25(1):51.
Score: 0.002
-
Serological responses to revaccination against HBV in HIV-positive patients born in the era of nationwide neonatal HBV vaccination. Liver Int. 2018 11; 38(11):1920-1929.
Score: 0.002
-
Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol. 2018 Feb 14; 24(6):725-736.
Score: 0.002
-
Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination. Liver Int. 2018 07; 38(7):1198-1205.
Score: 0.001
-
Analyses of Cellular Immune Responses in Ferrets Following Influenza Virus Infection. Methods Mol Biol. 2018; 1836:513-530.
Score: 0.001
-
Neutralizing antiinterferon-? autoantibodies causing disseminated Mycobacterium avium complex infection in an HIV-infected patient on successful combination antiretroviral therapy. AIDS. 2017 11 28; 31(18):2557-2559.
Score: 0.001
-
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy. Sci Rep. 2017 11 23; 7(1):16187.
Score: 0.001
-
Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. BMJ Open. 2017 Oct 16; 7(10):e015142.
Score: 0.001
-
Detecting exact breakpoints of deletions with diversity in hepatitis B viral genomic DNA from next-generation sequencing data. Methods. 2017 10 01; 129:24-32.
Score: 0.001
-
Incidence of acute hepatitis A among HIV-positive patients during an outbreak among MSM in Taiwan: Impact of HAV vaccination. Liver Int. 2018 04; 38(4):594-601.
Score: 0.001
-
Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG. Sci Rep. 2017 05 16; 7(1):1957.
Score: 0.001
-
Long-term Durability of Responses to 2 or 3 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Adults on Antiretroviral Therapy. J Infect Dis. 2017 02 15; 215(4):606-613.
Score: 0.001
-
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. PLoS One. 2016; 11(12):e0169228.
Score: 0.001
-
Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan. Sci Rep. 2016 10 25; 6:35779.
Score: 0.001
-
Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy. Vaccine. 2014 Feb 19; 32(9):1031-5.
Score: 0.001
-
Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol. 2012 Mar; 50(3):781-7.
Score: 0.001
-
Cost-effectiveness of detection of intestinal amebiasis by using serology and specific-amebic-antigen assays among persons with or without human immunodeficiency virus infection. J Clin Microbiol. 2008 Sep; 46(9):3077-9.
Score: 0.001